Public Company News
Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021
* As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in the safety analysis. ORR was 55.6%, and DCR was 88.9%. * The updated results from this Phase II study will be presented at an upcoming medical meeting. A phase III clinical study of KN046 in combinat...
2021-06-07 09:53
6499
CSOP Asset Management Ltd. Chooses SS&C to Support Operations
WINDSOR, Conn., June 7, 2021 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced thatHong Kong's CSOP Asset Management Ltd. has selected Eze Investment Suite for order management and portfolio accounting. Eze Investment Suite provides the flexibility CSOP required for ...
2021-06-07 09:00
11069
Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication
HANGZHOU, China and SHAOXING, China, June 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for ch...
2021-06-07 08:30
3856
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-07 08:00
8329
Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-07 08:00
8504
Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-07 08:00
8420
Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021
SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-07 08:00
8344
Ucommune International Ltd. Announces Unaudited First Quarter 2021 Financial Results
BEIJING, Jun. 5, 2021 /PRNewswire/ -- Ucommune International Ltd. (NASDAQ: UK) ("Ucommune" or the "Company"), a leading agile office space manager and provider inChina, today announced its unaudited financial results for the first quarter endedMarch 31, 2021. First Quarter 2021 Financial Highli...
2021-06-05 04:30
16591
Goldpac Financial Security Chip Operating System Accelerating the Replacement by Domestic One
HONG KONG, June 4, 2021 /PRNewswire/ -- As a reliable Fintech product and service providers, Goldpac Group Limited (stock code: 03315. HK) positively participatesand joins hands with domestic mainstream chip manufacturers to continue to carry out the research of financial security chip operat...
2021-06-04 17:15
8515
GWM's Building of Hydrogen Industry Ecology Boosts New Energy Revolution
BAODING, China, June 4, 2021 /PRNewswire/ -- Last month, GWM finished the first 70MPa type III bottle test for its hydrogen technology. Which marked another technical breakthrough the company made in hydrogen power industry after the hydrogen energy strategy released in March, and many innovative...
2021-06-04 14:54
18486
Sihuan Pharmaceutical (0460.HK) Obtained the Exclusive Distribution Right for LipiVage(R) Fat Collection System in Greater China and South Korea
HONG KONG, June 4, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that Meiyen Laboratory Inc, an Am...
2021-06-04 14:03
9714
Elekta Nomination Committee's proposed Board of Directors for the 2021 Annual General Meeting
STOCKHOLM, June 4, 2021 /PRNewswire/ -- The Nomination Committee of Elekta (EKTA-B.ST) proposes that the 2021 Annual General Meeting re-elect Board members Laurent Leksell, who is also proposed to be re-elected as Chairman of the Board, Caroline Leksell Cooke, Johan Malmquist, Wolfgang Reim, Jan Se...
2021-06-04 13:56
2442
Pearl Abyss Introduces New System "Mastery" in Shadow Arena
SEOUL, South Korea, June 4, 2021 /PRNewswire/ -- Pearl Abyss announced today
that the new system "Mastery" has been updated inShadow Arena.
2021-06-04 10:00
3072
Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021
SHANGHAI and HONG KONG, June 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-06-04 08:00
3729
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathy...
2021-06-04 02:00
2621
Sofwave™ Medical Raises $50M and Completes Initial Public Offering on the Tel Aviv Stock Exchange
TUSTIN, Calif., June 3, 2021 /PRNewswire/ -- On Wednesday, May 26, 2021, Sofwave™ Medical made its initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE). Sofwave's™, rapid market adoption enabled the listing on the Tel Aviv Stock Exchange. The company managed to raise$50 million at...
2021-06-03 23:32
13314
Maire Tecnimont Group's NextChem Awarded by TotalEnergies an Engineering Contract for a BioJet Plant in France
MILAN, June 3, 2021 /PRNewswire/ -- Maire Tecnimont S.p.A. (Milan: MT.MI) announces that its subsidiaryNextChem has been awarded a contract by TotalEnergiesto carry out a FEED and supply its technological know-how to implement a Sustainable Aviation Fuel (SAF) plant in Grandpuits, France, capabl...
2021-06-03 20:59
2637
Clarivate Partners with Explore IP to Support Canadian Innovation
Explore IP to integrate Derwent World Patents Index™ global patent data to help organizations increase the marketability of technologies LONDON, June 3, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innova...
2021-06-03 19:00
9137
Carrier Completes Acquisition of Guangdong Giwee Group, China-based HVAC Manufacturer
Acquisition to support Carrier's growth strategy and unlock new business opportunities CHARLOTTE, N.C., June 3, 2021 /PRNewswire/ -- Carrier today announced that it has completed the acquisition of a controlling stake of Guangdong Giwee Group (Giwee Group) and its subsidiaries, including Guangd...
2021-06-03 19:00
5853
Futu sustains leading position by obtaining "BBB-" credit rating from S&P, becoming first online brokerage in APAC with international rating
HONG KONG, June 3, 2021 /PRNewswire/ -- Futu Holdings Limited ("Futu") (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, is pleased to announce that it has obtained a "bbb" GCP (group credit profile) and a "BBB-" investment grade long-term issuer credit rat...
2021-06-03 18:41
14444
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 262 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 259 media titles]
2025-12-29 14:27Most Read
GreenTree Hospitality Group Ltd. Reports Third Quarter of 2025 Financial Results
2025-12-23 22:30
3805
Highway Holdings Plans to Acquire 51% of Regent-Feinbau Adermann GmbH
2025-12-23 20:00
3546
